Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.
Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.